Compare BioNTech SE - ADR (BNTX) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs KLA Corp. — how do they compare? BioNTech SE - ADR trades at $93.06 (market cap $23.31B), while KLA Corp. trades at $209.03 (market cap $261.92B). The key difference: KLA Corp. is far larger — about 11.2× BioNTech SE - ADR's market cap, and KLA Corp. pays a 0.46% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | KLAC | |
|---|---|---|
Market Cap | $23.31B | $261.92B |
Sector | Health | Technology |
52-Week High | $119.34 | $301.71 |
52-Week Low | $83.89 | $84.39 |
Enterprise Value | $6.60B | $263.17B |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
KLA Corporation (KLAC) trades at $209.16, up 8.52% over 24 hours, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock exhibits robust fundamentals with a 35.57% net income margin and 87.5% ROE, supported by a recent dividend hike and stock split. Analyst consensus is bullish with a $246.93 price target, though elevated valuation ratios like a P/E of 54.77 warrant caution.
Outlook remains positive driven by AI-driven semiconductor equipment demand, but risks include high valuation sensitivity and cyclical industry exposure. The stock offers growth potential with disciplined risk management advised given overbought technical conditions and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
